DSG2 Autoantibody Detection for ARVC Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) are clinically and genetically challenging, with low sensitivity and high costs, making early detection difficult and inefficient.
Innovation Solution
The presence of autoantibodies to desmoglein-2 (DSG2) in biological samples is used for diagnosing ARVC through binding with DSG2 or antigenic fragments, followed by detection with a non-human secondary antibody, and engineered T-cells with a DSG2 autoantibody antigen and cytoplasmic signaling domain are used for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Task Force criteria are used for diagnosing ARVC, then diagnostic coverage is achieved, but sensitivity remains low at 71% and costs are high
Solution Approach 1:
The patent extracts the key diagnostic information needed for ARVC diagnosis by focusing specifically on detecting autoantibodies to desmoglein-2, rather than requiring fulfillment of multiple Task Force criteria. This extraction approach maintains diagnostic reliability while simplifying the diagnostic procedure and reducing costs.
Solution Approach 2:
Instead of using the conventional approach of looking for structural and functional abnormalities through multiple tests, the patent inverts the diagnostic approach by detecting the presence of autoantibodies to desmoglein-2, which are the underlying cause of the disease. This inversion enables earlier detection before structural changes occur.
2Measurement precision
If multiple Task Force criteria tests are performed, then diagnostic coverage is achieved, but the procedure becomes expensive and time-consuming
Solution Approach 1:
The patent extracts the essential diagnostic information by focusing on a single biomarker - autoantibodies to desmoglein-2 - rather than requiring multiple tests. This extraction maintains diagnostic accuracy while significantly reducing the time required for diagnosis.
Solution Approach 2:
The patent performs preliminary detection of autoantibodies to desmoglein-2, which can be done early in the disease process before structural changes occur. This preliminary action enables earlier diagnosis without requiring progression through multiple diagnostic stages.
3Reliability
If genetic testing for ARVC mutations is performed, then 30-50% of cases are identified, but the majority of cases remain undiagnosed
Solution Approach 1:
The patent develops a universal diagnostic approach that detects autoantibodies to desmoglein-2, which applies to all ARVC cases regardless of genetic mutation status. This universal method overcomes the limitation of genetic testing that only identifies 30-50% of cases, providing broad applicability across all patient populations.
Solution Approach 2:
The patent uses autoantibodies to desmoglein-2 as an intermediary marker that bridges the gap between genetic predisposition and clinical manifestation. This intermediary approach allows detection of disease processes in both genetic and sporadic cases, expanding diagnostic coverage beyond what genetic testing alone can achieve.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a highly sensitive and specific diagnostic method for ARVC, correlating autoantibody levels with disease burden and enabling effective treatment by targeting DSG2 autoantibodies, thereby reducing ventricular arrhythmias and preventing heart failure.
Implementation Method 1
contacting the sample with a detectable non-human secondary antibody to the DSG2 autoantibody and determining whether or not DSG2 autoantibody is bound to the DSG2 or antigenic fragment by detecting binding of the detectable non-human secondary antibody to DSG2 autoantibody
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method of detecting a DSG2 autoantibody in a mammal is provided. The method includes contacting a biological sample obtained from a mammal with DSG2; and detecting the presence of DSG2 autoantibody bound to the DSG2 with a detectable anti- human antibody by detecting binding of the anti-human antibody to the DSG2 autoantibody. The method is useful to diagnose ARVC in a mammal.